NEW YORK (GenomeWeb News) – Certara said this week that it is working with the Critical Path Institute, C-Path, to create a physiologically-based pharmacokinetic model of the human lung using Certara's Simcyp Population-based simulator software that will be used to test new tuberculosis drugs.

According to the partners, the model will be useful for predicting the disposition of drugs within the lungs and the potential impact of disease progression on drug kinetics at different stages of TB infection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.